טוען...
Regulatory and clinical considerations for biosimilar oncology drugs
Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents—molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological...
שמור ב:
| הוצא לאור ב: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404762/ https://ncbi.nlm.nih.gov/pubmed/25456378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70365-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|